Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
McKinsey
Cantor Fitzgerald
AstraZeneca
Baxter
Medtronic
Mallinckrodt
Argus Health
Deloitte

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,748,481

« Back to Dashboard

Which drugs does patent 8,748,481 protect, and when does it expire?


Patent 8,748,481 protects AMITIZA and is included in one NDA. There has been one Paragraph IV challenge on Amitiza.

This patent has twenty-five patent family members in seventeen countries.

Summary for Patent: 8,748,481

Title:Method for treating gastrointestinal disorder
Abstract: The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:11/216,012
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► Subscribe► SubscribeMETHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► Subscribe► SubscribeMETHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,748,481

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20170003712► Subscribe
South Korea20140019006► Subscribe
South Korea20070048221► Subscribe
Japan2015166377► Subscribe
Japan2013049688► Subscribe
Japan2008511541► Subscribe
Israel181332► Subscribe
Spain2603381► Subscribe
European Patent Office1791545► Subscribe
China102885821► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
AstraZeneca
Farmers Insurance
Cantor Fitzgerald
US Department of Justice
Cerilliant
Fish and Richardson
Healthtrust
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot